Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Zappa

Showing results (161-170 of 188) with videos related to

Pageof 19
Sort By:
Pulmonology|January 17, 2021
Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patientsE Zampogna, G B Migliori, R Centis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)J Patnick, D Ransohoff, W Atkin, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|May 29, 2004
Comparing conventional and liquid-based smears from a consecutive series of 297 subjects referred to colposcopy assessmentM Confortini, P Bulgaresi, M P Cariaggi, et al.
British Journal of Cancer|January 15, 2009
Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?G Grazzini, C B Visioli, M Zorzi, et al.
AIDS (London, England)|August 16, 2001
Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 childrenM de Martino, P A Tovo, L Galli, et al.
Endocrine-Related Cancer|June 30, 2016
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumorsJ Cros, O Hentic, V Rebours, et al.
Breast (Edinburgh, Scotland)|March 19, 2019
Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancerA M W M Aarts, S W Duffy, S M E Geurts, et al.
Diagnostic Cytopathology|June 27, 2003
Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic processF M Carozzi, M P Cariaggi, L Bonardi, et al.
Tumori|July 1, 1996
Time trends of benign/malignant breast biopsy ratios a multicenter Italian studyS Ciatto, M R Del Turco, A Marrazzo, et al.
British Journal of Cancer|July 3, 2008
Do women >or=50 years of age need as much screening as women <50 years after they have had negative screening results?P Armaroli, F Gallo, A Bellomi, et al.
Pageof 19

Showing results (161-170 of 188) with videos related to

Sort By:
Pageof 19
Pulmonology|January 17, 2021
Functional impairment during post-acute COVID-19 phase: Preliminary finding in 56 patientsE Zampogna, G B Migliori, R Centis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2004
Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002)J Patnick, D Ransohoff, W Atkin, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology|May 29, 2004
Comparing conventional and liquid-based smears from a consecutive series of 297 subjects referred to colposcopy assessmentM Confortini, P Bulgaresi, M P Cariaggi, et al.
British Journal of Cancer|January 15, 2009
Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?G Grazzini, C B Visioli, M Zorzi, et al.
AIDS (London, England)|August 16, 2001
Puberty in perinatal HIV-1 infection: a multicentre longitudinal study of 212 childrenM de Martino, P A Tovo, L Galli, et al.
Endocrine-Related Cancer|June 30, 2016
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumorsJ Cros, O Hentic, V Rebours, et al.
Breast (Edinburgh, Scotland)|March 19, 2019
Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancerA M W M Aarts, S W Duffy, S M E Geurts, et al.
Diagnostic Cytopathology|June 27, 2003
Clinical impact (cost-effectiveness) of qualifying atypical squamous cells of undeterminate significance (ASCUS) in cases favoring a reactive or dysplastic processF M Carozzi, M P Cariaggi, L Bonardi, et al.
Tumori|July 1, 1996
Time trends of benign/malignant breast biopsy ratios a multicenter Italian studyS Ciatto, M R Del Turco, A Marrazzo, et al.
British Journal of Cancer|July 3, 2008
Do women >or=50 years of age need as much screening as women <50 years after they have had negative screening results?P Armaroli, F Gallo, A Bellomi, et al.
Pageof 19